The hepatitis C virus (HCV) genome was isolated during the late 1980s using molecular cloning techniques. It is recognized as the cause of most cases ofpercutaneously transmitted non-A, non-B hepatitis. Prevalence of antibodies to HCV (anti-HCV) in the general Australian population is 0.370. However; among regular intravenous drug users the prevalence exceeds 90%. The predominant risk factors for HCVare intravenous drug use, tattoos, exposure to blood products, occupational risk and ethnicity. In contrast to hepatitis B, stzual spread and vertical transmission of HCVfrom mother to neonate are relatively uncommon. The risk of acquiring HCVfrom a single HCV-contaminated needlestick accident is about S%. Most cases of acute HCVinfection are asymptomatic, but 50 to 80% progress to chronic disease. The percentage of those with chronic HCVprogressing to cirrhosis is not accurately known, but is probably 20%. Treatment strategies for HCK utilizing recombinant intetjerons, are proving useful in patients with mild to moderate liver disease, but fare less well in patients with cirrhosis.  Currently, there is no vaccine for hepatitis C, so pre-exposure prophylaxis is not possible. Equally, no post-exposure intervention,  for example with gamma globulin, has been shown to be beneficial, though there may be a role for early integeron thcrupy. 
The discovery and cloning of hepatitis C virus (HCV) in the late 1980s' was the result of a concerted effort to identify the causative agent of non-A, non-B hepatitis, a condition frequently recognized following blood transfusion or as a cause of hepatitis in individuals with other percutaneous risk factors, such as intravenous drug use (IVDU). The discovery was made possible because of extensive experience with the transmission of the non-A, non-B hepatitis agent to chimpanzees and the application of the tools provided by the rapidly developing field of molecular biology.
VIROLOGY
Most of the information now available concerning the structure of HCV has been deduced from the genomic sequence of the virus. HCV is a singlestranded, positive-sense RNA virus related to the flaviviridae2. The genome encodes a single precursor protein of approximately 3000 amino acids which is post-translationally cleaved into a number of structural and non-structural viral proteins. Sequence analysis of geographically dispersed isolates has shown that considerable heterogeneity exists and viral isolates have been divided into a number of genotypes on the basis of nucleotidc sequence alignment'.
Expression of viral-encoded proteins has allowed the development of serological assays to detect antibodies to HCV (anti-HCV), usually by enzyme-linked immunoassay. Generally, these assays employ three to four different virus-encoded proteins in order to detect antibodies. As these assays only detect the immune response to the virus, other methods have been developed to detect the viral genome directly, either by the use of polymerase chain reaction (PCR) or by the application of signal-amplified hybridization probes (branched chain assay).
Routine identification of the infected patient is made on the basis of information such as pcrcutaneous risk factors, abnormal serum aminotransferases and liver biopsy findings. When anti-HCV is present and there is biochemical or histological evidence of on-going hepatitis in the absence of other causes, it is reasonable to assume that the patient has an active infection with HCV Diagnosis is more difficult in cases with positive anti-HCV, absence of percutaneous risk factors and normal serum aminotransferases. Such cases are most often detected amongst blood donors and the possibility of a serological falsepositive exists. Supplementary investigations, such as PCR, can be useful in these casc9.
EPIDEMIOLOGY
While HCV is found throughout the world, the prevalence varies considerably, both between geographic regions and within community groups. Within most western countries the prevalence varies between 0.3 and 1.2% of the population, being 0.3% in Australian blood donorsj. However, in some regions, for example certain prefectures of Japan, parts of Mediterranean Europe and the Middle East, the prevalence is far higher. The reason for these areas of high prevalence is unknown, but probably does not relate to mother-to-neonate transmission (vertical transmission) as is the case with hepatitis B virus (HBV) infection6.'. Interestingly, some regions endemic for HBV infection show a low prevalence of HCV'.
Transmission of HCV is predominantly by the percutaneous route, consistent with the very high prevalence in regular IVDU$. Prior to the introduction of screening of donated blood for anti-HCV, the risk of acquiring infection from this source in Australia was approximately 0.3% per unit transfused5. Now posttransfusion hepatitis is an exceptionally rare event, attesting to the efficacy of anti-HCV screening'",". Other modes of transmission include tattoo?, sexual exposure and vertical transmissions from mother to neonate. Fortunately, sexual and vertical transmissions are uncommon, and studies to date suggest that the overall risk is less than 5% in both situa-tionS7.13-16.
Another risk, particularly relevant to the anaesthetic setting, is needlestick injury. The likelihood of acquiring HCV infection from a contaminated needlestick also seems to be 5%" or about 15 times the risk of acquiring HIV infection from this source. Interestingly, health care workers in a liver transplantation setting had a HCV seropositivity rate of 5.3%18, a rate many times that of the general community. At present there is no vaccine to protect against HCV and it is likely to be some time before an effective vaccine is developed. A recent study has noted that HCV infection is also more common in patients presenting for both elective and emergency surgery (two to three per cent of patients), being about five times the rate observed in blood donors from the same region 19. In Australia, no clear risk factor for acquisition of HCV infection can be ascertained in approximately 20% of patients (so-called sporadic infections). Thus, simply relying on risk factor questionnaires to identify high-risk individuals is not advised.
Nosocomial patient-to-patient transmission of HCV is well documented" and is particularly prevalent in chronic haemodialysis patients (24% of Anaesthesia and Intensive Care, Vol. 24, No. 2, April 1996 patients in one study)21. Surgeon-to-patient transmission has also been documented. A fascinating series of cases of patient-to-patient transmission, occurring during a minor surgical list, has been investigated in great detail. While the mode of transmission cannot be conclusively established, some features of the transmission implicated contamination of the anaesthetic circuit'*. Such events, when detected, merit intense investigation and should improve our knowledge of the ways in which HCV can be spread within the medical setting. Prevention strategies for medical procedure-related HCV infection rely on the application of "universal precautions"as recommended for HIV prevention.
CLINICAL SYNDROMES
Icteric hepatitis following acute HCV infection is rare. Indeed, most patients found to have chronic HCV give no past history of liver disease. In most of those with a history of acute hepatitis, markers for hepatitis A or HBV are present, indicating that the symptomatic episode was due to these viruses. Following acute HCV infection, a lag period of two to three months occurs before anti-HCV is detectable in serum23. Usually infected patients are detected following the finding of abnormal aminotransferases during a medical check-up or during investigation of an unrelated medical condition. As knowledge of this disease becomes more widespread in the community, additional patients with past percutaneous exposures are requesting anti-HCV screening through their general practitioner. A further group of patients is detected following the manifestation of signs of chronic liver disease or the development of hepatocellular carcinoma.
There is no doubt that HCV infection frequently progresses to chronic liver disease, and this seems to occur in the majority of cases. Chronic infection which has not progressed to decompensated liver disease is also often asymptomatic. Overall approximately 50% of patients report symptoms in association with chronic HCV infection, the most common being chronic fatigue and non-specific right upper quadrant abdominal discomfort. Complications that arise in patients with chronic HCV infection are most conveniently divided into hepatic and extra-hepatic manifestations ( Table 1 ). Hepatic complications are the same as for cirrhosis of any aetiology and include portal hypertension, hepatocellular failure and the development of hepatocellular carcinoma. Extrahepatic manifestations include constitutional symptoms, porphyria cutanea tarda and, rarely, essential mixed cryoglobulinaemia. In the anaesthesia/surgical setting the presence of hepatic cirrhosis is associated with an increase in morbidity and mortality. Indeed, a mortality rate of SO% has been observed in patients with severe liver disease undergoing open cholecystectomyz4. Factors shown to be associated with increased anaesthesia/surgical mortality include prolonged prothrombin time, low serum albumin and the presence of infection as indicated by an elevated leucocyte countz5. Therefore major surgical procedures should be avoided in patients with severe liver disease wherever possible,
PROGNOSIS AND TREATMENT
The question of prognosis in relation to chronic HCV infection is a hotly debated topic. It has been suggested that chronic HCV is a slowly progressive and often benign diseasez6. While this may be so in some patients, it ignores the fact that decompensated liver disease secondary to HCV infection is now the most common indication for liver transplantation in many centres and that HCV is a common cause of hepatocellular carcinoma in geographic regions in which HBV is not endemic". It is also clear that in most patients the time to development of cirrhosis is long, probably of the order of 15 years or more. Indeed, in patients developing hepatocellular carcinoma the duration of disease tends to be even longer. However, HCV infection is often acquired early in life, for example, in the late teens in association with IVDU. Thus cirrhosis and its attendant complications may become apparent by the third or fourth decades. Moreover, other factors that inde-pendently cause liver damage, such as excessive alcohol consumption or infection with other hepatitis viruses*', may act synergistically with HCV to cause cirrhosis.
At present, interferons are the only recognized treatment for HCV infection. Both OL-and B-interferons have been shown to be useful while g-interferon is of no benefit. Recombinant a-interferon (IFN) is now licensed for the treatment of chronic HCV infection in many countries. There are now more than 40 randomized trials documenting sustained normalization of serum aminotransferases following IFN treatment in some patients. Indeed, patients have now been followed for as long as six years after ceasing therapy with IFN with posttreatment serum aminotransferases remaining totally normal and serum remaining free of HCV RNA as determined by PCR". The optimum duration of IFN treatment seems to be approximately one year, and in non-cirrhotic patients a sustained response rate of approximately 30 to 40% can be expected"l"'. A number of factors have been identified that are associated with a decreased response rate including cirrhosis32, HCV genotype lx3 and high viral loadX4. Clearly, some of these variables may be interrelated. There is little argument that more effective treatments for chronic HCV are required. In this regard, a pilot study using IFN in combination with the nucleoside analogue ribavirin has produced some interesting findings". Large scale studies using this combination will begin in the near future.
Liver transplantation is being increasingly used in patients with end-stage liver disease secondary to chronic HCV infection. While initial survival rates approximate those for other forms of liver disease, HCV infection frequently recurs in the transplanted liver'", 37. As time progresses the natural history of HCV infection following transplant will be ascertained, but it is likely some patients will lose graft function due to progressive HCV-induced liver damage.
The role of IFN treatment in acute HCV infection has been examined in a small number of studies. Overall, there is evidence that treatment commenced during or shortly after acute hepatitis (usually determined by elevated aminotransferases following an exposure) decreases the rate of progression to chronic disease. This form of therapy may be useful in those: with acute infection following occupational or other documented exposures.
